Zobrazeno 1 - 10
of 15
pro vyhledávání: '"F Gomez de Rueda"'
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38549a6348b5f5e9e2a0156f8224d225
https://doi.org/10.1136/ejhpharm-2023-eahp.104
https://doi.org/10.1136/ejhpharm-2023-eahp.104
Autor:
F Gomez de Rueda, R Castillejo García, B Cancela Díez, P Aceituno Madero, MA Calleja Hernandez
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e56eb38dca83b70802dd9896d117621a
https://doi.org/10.1136/ejhpharm-2022-eahp.122
https://doi.org/10.1136/ejhpharm-2022-eahp.122
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Hyperammonaemia is known as a metabolic disturbance due to deficiency of some enzymes of the ‘urea cycle’, a biochemical process where nitrogenous products are purified from the organism and whose accumulation leads to n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b7e2ed05259bd02d8c25481f2a4d629
https://doi.org/10.1136/ejhpharm-2021-eahpconf.174
https://doi.org/10.1136/ejhpharm-2021-eahpconf.174
Autor:
MJ Barbero Hernandez, R Claramunt García, A López López, A Jiménez Morales, C Alarcon-Payer, F Gomez-de Rueda
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Immunotherapy has broken new ground in the treatment of multiple myeloma, with the introduction of monoclonal antibodies into the therapeutic arsenal, representing a paradigm shift in treatment. Daratumumab is a human monocl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc80ad8bf46d13e66fc71bbfbdd82614
https://doi.org/10.1136/ejhpharm-2020-eahpconf.257
https://doi.org/10.1136/ejhpharm-2020-eahpconf.257
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Pharmaceutical care (PC) is the ‘supply of medicines with the purpose of achieving concrete results that improve the quality of life of the patient’, being related to the global process of prescription through pharmaceutical interventi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4d6dd2a6e0f68a62b9a69bfccf76070
https://doi.org/10.1136/ejhpharm-2019-eahpconf.562
https://doi.org/10.1136/ejhpharm-2019-eahpconf.562
Publikováno v:
European Journal of Hospital Pharmacy. 22:A124.2-A124
Background Bortezomib is an expensive drug with a very short stability. For subcutaneous administration each vial should be reconstituted with 1.4 mL of NaCl 0.9% (2.5 mg/mL). According to the manufacturer, reconstituted it is stable at 25°C for onl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3bf63793d432374244817afac22539a
https://doi.org/10.1136/ejhpharm-2015-000639.300
https://doi.org/10.1136/ejhpharm-2015-000639.300
Autor:
MT Gómez de Travecedo, MT Moreno Carvajal, R Gavira Moreno, JF Sierra Sánchez, P Gómez Germá, F Gomez De Rueda, EJ Alegre Del Rey, R Gázquez Pérez, V González Rosa
Publikováno v:
European Journal of Hospital Pharmacy. 21:A200.1-A200
Background No head-to-head clinical trials have been published comparing aflibercept and bevacizumab for the neovascular form of age-related macular degeneration (AMD). Adjusted indirect comparisons may provide useful information on the relative effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a294c70e21a48f808101c107eaf21412
https://doi.org/10.1136/ejhpharm-2013-000436.488
https://doi.org/10.1136/ejhpharm-2013-000436.488
Autor:
R Gavira Moreno, P Gómez Germá, V González Rosa, MM Viña Romero, F Gutiérrez Nicolás, MT Moreno Carvajal, R Gázquez Pérez, F Gomez De Rueda, MT Gómez de Travecedo y Calvo, A. Almendral Vicente
Publikováno v:
European Journal of Hospital Pharmacy. 20:A4.3-A5
Background Improved survival associated with tyrosine kinase inhibitor (TKI) treatment has transformed chronic myeloid leukaemia (CML) into a long-term disease, but therapeutic success is challenged with poor medicines adherence. Controlling side eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d08992432d2f6397d34ddb95f74d767
https://doi.org/10.1136/ejhpharm-2013-000276.011
https://doi.org/10.1136/ejhpharm-2013-000276.011
Autor:
P Gómez Germá, MA Almendral Vicente, V González Rosa, F Gomez De Rueda, R Gavira Moreno, M. Lobato Ballesteros, MT Gómez de Travecedo y Calvo, J.P. DÍaz López, R Gázquez Pérez, MT Moreno Carvajal
Publikováno v:
European Journal of Hospital Pharmacy. 20:A7.1-A7
Background Medication errors with antineoplastic drugs may be catastrophic due to the drugs’ high toxicity and narrow therapeutic index. Purpose To assess antineoplastic medication errors in terms of frequency, type of error and severity for patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::840aeb5325d78ce44962780a0faae89b
https://doi.org/10.1136/ejhpharm-2013-000276.018
https://doi.org/10.1136/ejhpharm-2013-000276.018
Autor:
R Gavira Moreno, F Gomez De Rueda, J.P. DÍaz López, MT Gómez de Travecedo, C. Cano Corral, M. Lobato Ballesteros, V González Rosa, A. Almendral Vicente, MT Moreno Carvajal, P Gómez Germá
Publikováno v:
European Journal of Hospital Pharmacy. 19:167.1-167
Background Oral chemotherapy agents are medications that were dispensed in pharmacies usually but since the entry into force of an order regional president in January 2011 became hospital dispensing. Purpose To analyse the economic and healthcare imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7418c5a5ba4cfdd1daf67e8864b651e3
https://doi.org/10.1136/ejhpharm-2012-000074.217
https://doi.org/10.1136/ejhpharm-2012-000074.217